

RECEIVED  
DEC 03 2001  
TECH CENTER 1600/2900



00270

PATENT TRADEMARK OFFICE

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> (to be used for all correspondence after initial filing)	Application Number	09/913,911	
	Filing Date	08/21/2001	
	First Named Inventor	Daniela Santoli et al	
	Group Art Unit	1633	
	Examiner Name		
Total Number of Pages in This Submission	9	Attorney Docket Number	WST88AUSA

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):  Copies of (29) documents are attached herewith.
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Mary E. Bak, Esquire Howson and Howson
Signature	<i>Mary E. Bak</i>
Date	Nov. 29, 2001

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: _____			
Typed or printed name			
Signature		Date	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



00270

PATENT TRADEMARK OFFICE

WST88AUSA

#4

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

Daniela Santoli et al

Appln. No. 09/913,911

Filed: August 21, 2001

For: METHOD OF MODIFYING  
CYTOTOXIC CELLS AND USES  
THEREOFAssistant Commissioner for Patents  
Washington, DC 20231

) Group Art. Unit. 1613

) DEC 03 2001

) Examiner:

TECH CENTER 1600/2900

)

)

)

)

)

) November 29, 2001

)

)

)

01 NOV 29 PM 3:21

RECEIVED  
TECH CENTER 1600/2900**INFORMATION DISCLOSURE STATEMENT**

Sir:

Applicants submit to the Examiner the attached Form PTO/SB/08A/B document listing and this paper pursuant to 37 CFR §1.56 and § 1.97-1.98. Form PTO/SB/08A/B is attached and copies of the references are enclosed herewith.

According to 37 CFR §1.98(d), Applicants have not enclosed copies of documents (AC), (AD), (AE), (AL), and (AR) through (AV) as these documents were previously cited in the International Search Report in prior International Application No. PCT/US00/04548, filed February 23, 2000. This application is a 371 of that International patent application. A copy of the International Search Report is attached hereto.

This Information Disclosure Statement is submitted more than three months from the filing date of this application, but prior to receipt of an Office Action on the merits. Therefore, no fees are believed due. However, the Director of the U. S. Patent and Trademark Office is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees paid on the filing, or during prosecution of this application to Deposit Account No. 08-3040.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Substitute for Form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/913,911
				Filing Date	August 21, 2001
				First Named Inventor	Daniela Santoli et al
				Group Art Unit	1633
				Examiner Name	
Sheet	2	of	6	Attorney Docket Number	WST88AUSA

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	AF	5,747,024	B1	K. Grabstein	05/05/1998	
	AG	5,660,824	B1	K. Grabstein	08/26/1997	
	AH	6,022,538	B1	D. Santoli	02/08/2000	

FOREIGN PATENT DOCUMENTS								
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Substitute for Form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/913,911
				Filing Date	August 21, 2001
				First Named Inventor	Daniela Santoli et al
				Group Art Unit	1633
				Examiner Name	
Sheet	3	of	6	Attorney Docket Number	WST88AUSA

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS				
Examiners Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	AR	A. GAMERO et al, "Interleukin 15 Induction of Lymphokine-activated Killer Cell Function Against Autologous Tumor Cells in Melanoma Patient Lymphocytes by a CD18-Dependent, Perforin-related Mechanism", Cancer Research, 55:4988-4994 (November, 1995)		
	AS	A. CESANO et al, "Two Unique Human Leukemic T-Cell Lines Endowed with a Stable Cytotoxic Function and a Different Spectrum of Target Reactivity Analysis and Modulation of Their Lytic Mechanisms", In Vitro Cell. Dev. Biol., 28A:648-656 (September-October, 1992)		
	AT	A. CESANO et al, "Effects of Lethal Irradiation and Cyclosporin A Treatment on the Growth and Tumoricidal Activity of a T Cell Clone Potentially Useful in Cancer Therapy", Cancer Immunol. Immunother., 40:139-151 (1995)		
	AU	D. SANTOLI et al, "Synergistic and Antagonistic Effects of IL-1 $\alpha$ and IL-4, Respectively, on the IL-2-Dependent Growth of a T Cell Receptor- $\gamma\delta^+$ Human T Leukemia Cell Line", J. Immunol., 144(12):4703-4711 (June, 1990)		
	AV	J. DISANTO, "Cytokines: Shared Receptors, Distinct Functions", Current Biology, 7:R424-R426 (July, 1997)		
	AW	B. ROUSE et al, "Consequences of Exposure to Ionizing Radiation for Effector T Cell Function in Vivo", Viral Immunology, 2(2):69-78 (1989)		
	AX	T. HAN et al, "Stimulating Capacity of Blast Cells from Patients with Chronic Myelocytic Leukaemia, in Blastic Crisis in 'one-way' Mixed Lymphocyte Reaction: Lack of Evidence for T Lymphoblastic Conversion", Immunology, 35:299-305 (1978)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Substitute for Form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/913,911
				Filing Date	August 21, 2001
				First Named Inventor	Daniela Santoli et al
				Group Art Unit	1633
				Examiner Name	
Sheet	4	of	6	Attorney Docket Number	WST88AUSA

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiners Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AY	K. FOON, "Biological Response Modifiers: The New Immunotherapy", Cancer Research, 49:1621-1639 (April, 1989)	
	AZ	T. BOON, "Tumor Antigens Recognized by Cytolytic T Lymphocytes: Present Perspectives for Specific Immunotherapy", Int. J. Cancer, 54:177-180 (1993)	
	AAR	M. OSBAND et al, "Problems in the Investigational Study and Clinical Use of Cancer Immunotherapy", Immunology Today, 11(6):103-105 (1990)	
	AAS	A. CESANO et al, "Phase I Clinical Trial with a Human Major Histocompatibility Complex Nonrestricted Cytotoxic T-Cell Line (TALL-104) in Dogs with Advanced Tumors", Cancer Research, 56:3021-3029 (July, 1996)	
	AAT	R. O'CONNOR et al, "Growth Factor-Dependent Differentiation Along the Myeloid and Lymphoid Lineages in an Immature Acute T Lymphocytic Leukemia", J. Immunol., 145(11):3779-3787 (December, 1990)	
	AAU	S. CHAN et al, "Mechanisms of IFN-γ Induction by Natural Killer Cell Stimulatory Factor (NKSF/IL-12)", J. Immunol., 148(1):92-98 (January 1992)	
	AAV	R. O'CONNOR et al, "Growth Factor Requirements of Childhood Acute T-Lymphoblastic Leukemia: Correlation Between Presence of Chromosomal Abnormalities and Ability to Grow Permanently In Vitro", Blood, 77(7):1534-1545 (April, 1991)	
	AAW	A. CESANO et al, "Cellular and Molecular Mechanisms of Activation of MHC Nonrestricted Cytotoxic Cells by IL-12", 151:2943-2957 (1993)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Substitute for Form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/913,911
				Filing Date	August 21, 2001
				First Named Inventor	Daniela Santoli et al
				Group Art Unit	1633
				Examiner Name	
Sheet	5	of	6	Attorney Docket Number	WST88AUSA

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiners Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AAX	S. VISONNEAU et al, "A Revertant TCR $\gamma\delta$ + Cell Clone Which has Lost MHC Nonrestricted Cytotoxic Activity but Retains Redirected Killing Upon Stimulation of the CD3 Receptor", Cell. Immunol., 165:252-265 (1995)	
	AAY	A. CESANO et al, "Role of CD38 and its Ligand in the Regulation of MHC-Nonrestricted Cytotoxic T Cells", J. Immunol., 160:1106-1115 (1998)	
	AAZ	J. GIRI et al, "IL-5, a Novel T Cell Growth Factor that Shares Activities and Receptor Components with IL-2", J. Leuko. Biol., 57(5):763-766 (May, 1995)	
	BR	L. QUINN et al, Interleukin-15: A Novel Anabolic Cytokine for Skeletal Muscle", Endocrinol., 136(8):3669-3672 (August, 1995)	
	BS	W. CARSON et al, "Endogenous Production of Interleukin 15 by Activated Human Monocytes is Critical for Optimal Production of Interferon-gamma by Natural Killer Cells in Vitro", J. Clin. Invest., 96(6):2578-2582 (December, 1995)	
	BT	J. JONULEIT et al, "Induction of IL-15 Messenger RNA and Protein in Human Blood-Derived Dendritic Cells", J. Immunol., 158(6):2610-2615 (March, 1997)	
	BU	V. GARCIA et al, "IL-15 Enhances the Response of Human $\gamma\delta$ T Cells to Nonpeptide Microbial Antigens", J. Immunol., 160(9):4322-4329 (May, 1998)	
	BV	A. MORI et al, "IL-15 Promotes Cytokine Production of Human T Helper Cells", J. Immunol., 156(7):2400-2405 (April, 1996)	
	BW	M. NIETO et al, Interleukin-15 Induces Adhesion Receptor Redistribution in T Lymphocytes", Euro. J. Immunol., 26(6):1302-1307 (June, 1996)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Substitute for Form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/913,911
				Filing Date	August 21, 2001
				First Named Inventor	Daniela Santoli et al
				Group Art Unit	1633
				Examiner Name	
Sheet	6	of	6	Attorney Docket Number	WST88AUSA

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS				
Examiners Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	BX	M. KENNEDY et al, "Characterization of Interleukin-15 (IL-15) and the IL-15 Receptor Complex", J. Clin. Immunol., 16(3):134-143 (May, 1996)		
	BY	A. ANGIOLILLO et al, "Interleukin-15 Promotes Angiogenesis in vivo", Biochem. Biophys. Res. Comm., 233(1):231-237 (April, 1997)		
	BZ	P. ALLAVENA et al, "IL-15 is Chemotactic for Natural Killer Cells and Stimulates their Adhesion to Vascular Endothelium", J. Leuko. Biol., 61(6):729-735 (June, 1997)		
	BBR	R. EVANS et al, IL-15 Mediates Anti-tumor Effects after Cyclophosphamide Injection of Tumor-Bearing Mice and Enhances Adoptive Immunotherapy: The Potential Role of NK Cell Subpopulations", Cell. Immunol., 179(1):66-73 (July, 1997)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Substitute for Form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/913,911
				Filing Date	August 21, 2001
				First Named Inventor	Daniela Santoli et al
				Group Art Unit	1633
				Examiner Name	
Sheet	1	of	6	Attorney Docket Number	WST88AUSA

U.S. PATENT DOCUMENTS						
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	AA	5,126,132	B1	S. Rosenberg	06/30/1992	
	AB	5,272,082	B1	D. Santoli	12/21/1993	
	AC	5,820,856	B1	D. Santoli	10/13/1998	
	AD	5,702,702	B1	D. Santoli	12/30/1997	
	AE	5,683,690	B1	D. Santoli	11/04/1997	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	AL	WO	WO94/26284	A1	D. Santoli	11/24/1994		
	AM	WO	WO98/48630	A1	D. Santoli	11/05/1998		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.



. The Examiner is respectfully requested to consider the documents identified in this paper and in the attached Form PTO/SB/08A/B during the course of the examination of this application.

Respectfully submitted,

HOWSON AND HOWSON  
Attorneys for the Applicants

By Mary E. Bak  
Mary E. Bak  
Registration No. 31,215  
Spring House Corporate Center  
Box 457  
Spring House, PA 19477  
Telephone: (215) 540-9206  
Telefacsimile: (215) 540-5818